AmgenvsCoherus Oncology

AMGN and CHRS stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$457.93

Value $247B

-0.95%
AMGN's page

CHRS

Coherus Oncology, Inc.

$0.48

Value $72M

-5.34%
CHRS's page

Amgen (AMGN) has a market value of $247B and Coherus Oncology (CHRS) $72M. Over the last year, with dividends, AMGN moved +39.7% and CHRS -59.7%. Dividend yield: AMGN 2.17%, CHRS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$247B

    CHRS$72M

    AMGN is 3,442 times CHRS

  • Revenue, 12 months

    AMGN$38.9B

    CHRS$54M

    AMGN is 725 times CHRS

  • Net income, 12 months

    AMGN$9.4B

    CHRS-$136M

  • Operating margin

    AMGN32.4%

    CHRS-275.9%

    308.3 points apart

  • ROIC

    AMGN16.2%

    CHRS-186.5%

    202.7 points apart

  • P/E

    AMGN26.3

    CHRS–

  • Dividend yield

    AMGN2.2%

    CHRS0.0%

    2.2 points apart

  • 5-year return

    AMGN+158.3%

    CHRS-97.5%

    255.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+158.3%

CHRS-97.5%

010020020222023202420252026
Returns by period
PeriodAMGNWith dividendsCHRSWith dividends
1 year since November 14, 2025+39.7%Price +36.0%-59.7%Price -59.7%
3 years since November 17, 2023+87.3%+23.3% a yearPrice +72.5%-77.5%-39.2% a yearPrice -77.5%
5 years since November 16, 2021+158.3%+20.9% a yearPrice +123.0%-97.5%-52.1% a yearPrice -97.5%
10 years since November 17, 2016+315.7%+15.3% a yearPrice +210.8%-98.3%-33.4% a yearPrice -98.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenCHRSCoherus Oncology

Valuation

AMGNCHRS
Valuation
Price$457.93$0.48
Market value$247B$72M
Enterprise value (EV)$288B–
P/E26.3–
P/E, 5-year median23.0–
P/B17.22.8
EV/EBIT22.8–
Free cash flow yield3.9%–

Results and growth

AMGNCHRS
Results and growth
Revenue, 12 months$38.9B$54M
Net income, 12 months$9.4B-$136M
Free cash flow, 12 months$9.6B-$174M
Earnings per share, 12 months$17.25-$1.00
Revenue growth, year on year10.0%59.8%
Revenue growth a year, past+7.6%over 5 years-38.4%over 5 years
EPS growth a year, past+2.9%over 5 years-2.5%over 5 years

Margins and returns on capital

AMGNCHRS
Margins and returns on capital
Gross margin70.9%69.8%
Operating margin32.4%-275.9%
Net margin24.1%-253.4%
ROIC16.2%-186.5%
ROE87.8%-216.8%

Balance sheet

AMGNCHRS
Balance sheet
Cash$13.2B$84M
Total debt$54.0B–
Net debt / EBITDA2.3–
Interest cover4.8×-15.5×

Dividends and buybacks

AMGNCHRS
Dividends and buybacks
Dividend yield2.2%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.2%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or CHRS

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Coherus Oncology?

By market value, Amgen ($247B) is about 3,441.8 times Coherus Oncology ($72M), at today's prices.

How did AMGN and CHRS stock do over the last 10 years?

Since November 17, 2016, AMGN's price moved +210.8% and CHRS's -98.3%. With dividends: AMGN +315.7% (+15.3% a year), CHRS -98.3% (-33.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or CHRS?

The dividend yield at today's price is 2.17% for Amgen and none for Coherus Oncology. Over the last twelve months they paid $9.94 and – per share.

Which has the higher profit margins, Amgen or Coherus Oncology?

Over the last twelve months, the net margin was 24.1% for Amgen and -253.4% for Coherus Oncology, and the operating margin 32.4% and -275.9%. Revenue was $38.9B and $54M.

Which is the better investment, Amgen or Coherus Oncology?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.